Terminology Service for NFDI4Health
Palbociclib Isethionate
Go to external page
http://purl.obolibrary.org/obo/NCIT_C120259
The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. [ ]
Term info
Label
Palbociclib Isethionate
Synonyms
- 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate)
- PALBOCICLIB ISETHIONATE
- PD 0332991-0054
- PF-00080665-73
- Palbociclib Isethionate
Subsets
NCIT_C116978, NCIT_C128784, NCIT_C63923, NCIT_C157711, NCIT_C116977, NCIT_C157712
CAS Registry
827022-33-3
Chemical Formula
C24H29N7O2.C2-H6-O4-S
Contributing Source
CTRP, FDA
Display Name
Palbociclib Isethionate
FDA UNII Code
W1NYL2IRDR
Preferred Name
Palbociclib Isethionate
Semantic Type
Pharmacologic Substance, Organic Chemical
UMLS CUI
C3896941
code
C120259
Term relations
Subclass of:
- Antineoplastic Enzyme Inhibitor
- Cyclin-Dependent Kinase Inhibitor
- Chemical_Or_Drug_Has_Physiologic_Effect some Gene Regulation Process
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Enzyme Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Has_Physiologic_Effect some Protein Phosphorylation Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of G1 Phase
- Chemical_Or_Drug_Affects_Gene_Product some Cyclin-Dependent Kinase
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of G2 to M Transition